Paratek goes 3-for-3 in PhIII, but antibiotic stumbles on side effect profile
Paratek’s antibiotic omadacycline has now gone three for three in Phase III — setting up a pitch to the FDA — but the data on an oral version of the antibiotic had some troubling side effects, raising new questions about its potential.
On the efficacy side oral omadacycline looked solid for acute bacterial skin and skin structure infections (ABSSSI), coming in noninferior to linezolid with an 87.5% response rate for their antibiotic against 82.5% for the industry standard.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
